Cannabis Use Disorder (CUD) is a recognized medical condition that affects millions of people who struggle to control their cannabis use despite negative consequences. Like other forms of THC poisoning, CUD can significantly impact physical health, mental health, relationships, work, and daily functioning. As researchers explore new treatment options, GLP-1 medications-the same drugs used for diabetes and weight management-have shown some promising associations with reduced cannabis use disorder in recent research.

A comprehensive review of the medical literature examined whether GLP-1 receptor agonist medications compare favorably to standard treatment in reducing cannabis use and associated symptoms among individuals with cannabis use disorder. The findings suggest potential promise, but also highlight significant limitations and the need for more rigorous research.

Understanding Cannabis Use Disorder as THC Poisoning

Cannabis Use Disorder is a diagnosable condition characterized by a problematic pattern of cannabis use that leads to significant impairment or distress. It’s recognized in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and can range from mild to severe. Like other forms of THC poisoning, CUD develops when chronic cannabis use disrupts normal brain function and creates dependence.

People with CUD may experience:

• Inability to cut down or control cannabis use despite wanting to
• Spending significant time obtaining, using, or recovering from cannabis
• Cravings and strong urges to use cannabis
• Continued use despite physical or psychological problems
• Tolerance (needing more to achieve the same effect)
• Withdrawal symptoms when stopping

This condition represents one way that chronic THC exposure can poison the body’s systems, creating a cycle of dependence that’s difficult to break. Currently, there are no FDA-approved medications specifically for treating cannabis use disorder, which makes any potential new treatment options worth exploring.

What Are GLP-1 Medications?

GLP-1 (glucagon-like peptide-1) receptor agonists are medications originally developed for type 2 diabetes. They work by mimicking a hormone that helps regulate blood sugar and appetite. More recently, some formulations have been approved for weight management because they can reduce appetite and slow stomach emptying.

These medications include:

• Semaglutide (Ozempic, Wegovy)
• Liraglutide (Saxenda, Victoza)
• Dulaglutide (Trulicity)
• Exenatide (Byetta, Bydureon)

GLP-1 medications have also been studied for their potential effects on substance use behaviors, including alcohol use disorder and other addictions. This has led researchers to investigate whether they might help people with cannabis use disorder reduce or stop their cannabis use.

The Research Findings

A systematic review searched over 138 million academic papers to find studies examining how GLP-1 receptor agonist medications compare to standard treatment in reducing cannabis use among individuals with cannabis use disorder. The search identified one large retrospective cohort study that provides preliminary evidence, though with important limitations.

The Study

The study examined electronic health records from 681,268 patients across 61 large healthcare organizations in the United States. It compared patients who were prescribed semaglutide (a GLP-1 medication) to patients who received other medications for their conditions. The study looked at two populations:

• Patients with obesity (85,223 total)
• Patients with type 2 diabetes (596,045 total)

The comparison groups received non-GLP-1RA medications for their conditions (anti-obesity medications or anti-diabetes medications, respectively). The study tracked cannabis use disorder diagnoses over a 12-month follow-up period.

Key Findings

The study found that semaglutide was associated with lower rates of cannabis use disorder diagnoses compared to other medications:

In patients with obesity:

• 44% lower risk of developing new cannabis use disorder (incident CUD)
• 38% lower risk of recurring cannabis use disorder (recurrent CUD)

In patients with type 2 diabetes:

• 60% lower risk of developing new cannabis use disorder (incident CUD)
• The association with recurring CUD did not reach statistical significance

These are substantial reductions. For example, in the obesity population, incident CUD occurred in 0.28% of semaglutide patients versus 0.48% of comparison patients. For recurrent CUD, the rates were 13.0% versus 20.4%-a difference of 7.4 percentage points.

Subgroup Analyses

The study examined whether the effects varied across different demographic groups. The protective associations were generally consistent across:

• Gender
• Age groups

However, the protective effect was not observed in Black patients, which is an important finding that warrants further investigation. This could relate to various factors including differences in healthcare access, treatment patterns, or biological responses, and highlights the need for research that specifically examines how treatments work across diverse populations.

Important Limitations

While these findings are intriguing, it’s crucial to understand the study’s limitations:

Observational Design

This was a retrospective cohort study, not a randomized controlled trial. This means:

• It cannot prove that semaglutide caused the lower CUD rates
• There could be other factors explaining the association
• The study looked back at existing medical records rather than actively testing the medication

Different Populations

The study examined people with obesity and type 2 diabetes who were prescribed semaglutide for those conditions, not people specifically seeking treatment for cannabis use disorder. This means:

• The findings may not apply to people whose primary concern is CUD
• The patients may have had different motivations or support systems
• The context of treatment was different than it would be for CUD-specific treatment

Limited Outcome Measures

The study measured cannabis use disorder diagnoses through electronic health records, not direct measures of cannabis use. It didn’t track:

• Actual cannabis use frequency or quantity
• Cannabis cessation rates
• Withdrawal symptoms
• Cravings
• Quality of life measures
• Validated CUD severity assessments

Missing Information

Critical information was not available, including:

• Baseline cannabis use patterns
• CUD severity at the start
• Specific dosing protocols
• Route of administration details
• Safety data specific to CUD patients
• Adverse event rates
• Discontinuation rates due to side effects

No Standard CUD Treatment Comparison

The comparison groups received medications for obesity or diabetes, not standard treatments for cannabis use disorder. Standard CUD treatment typically involves:

• Behavioral interventions (cognitive-behavioral therapy, motivational enhancement therapy)
• Support groups
• Contingency management
• Tapering strategies
• Support for withdrawal symptoms

The study didn’t compare semaglutide to these approaches, so we don’t know how it would perform against established CUD treatments.

What This Means for Cannabis Use Disorder

The findings suggest that GLP-1 medications like semaglutide might have potential for helping people with cannabis use disorder, but we need much more research to know for certain. The associations are promising, but they’re just that-associations, not proven effects.

The Need for Randomized Controlled Trials

The research review concluded that “randomized controlled trials with comprehensive cannabis use assessments are needed to establish efficacy and safety of GLP-1 receptor agonists for treating cannabis use disorder.”

Proper studies would need to:

• Randomly assign people with CUD to receive GLP-1 medications or standard treatment
• Measure actual cannabis use (not just diagnoses)
• Track CUD symptoms, cravings, and withdrawal
• Compare against established CUD treatments
• Monitor safety and side effects
• Follow participants long enough to see if effects are sustained

Until such research is conducted, we cannot confidently say that GLP-1 medications are effective for treating cannabis use disorder.

Why This Matters

Cannabis Use Disorder is a significant public health concern. Many people struggle to stop using cannabis despite negative consequences, and there are currently no FDA-approved medications to help. If GLP-1 medications could provide a new treatment option, that would be valuable-but we need proper evidence first.

The fact that semaglutide showed associations with lower CUD rates in other populations suggests it’s worth investigating further. However, we shouldn’t assume it will work for CUD without proper research.

Potential Mechanisms

While the study didn’t investigate mechanisms, researchers have proposed several ways GLP-1 medications might affect substance use:

Appetite and Reward Pathways

GLP-1 medications affect brain regions involved in reward and motivation, which overlap with areas affected by substance use. By modulating these pathways, they might reduce the rewarding effects of cannabis and decrease cravings.

Metabolic Effects

Some research suggests that metabolic factors might influence substance use behaviors. GLP-1 medications’ effects on metabolism could potentially play a role, though this is speculative.

Indirect Effects

The medications might work indirectly through:

• Improved overall health and well-being
• Better sleep (which can affect substance use)
• Reduced stress (through metabolic improvements)
• Changes in other behaviors that affect cannabis use

However, these are hypotheses. We need research specifically designed to understand how GLP-1 medications might affect cannabis use if they do.

What This Means for People with Cannabis Use Disorder

If you’re struggling with cannabis use disorder and wondering whether a GLP-1 medication might help, here’s what you should know:

There’s Preliminary Evidence, But Not Proof

The study found promising associations, but it wasn’t designed to test whether GLP-1 medications actually help people with CUD stop using cannabis. We need proper clinical trials to answer that question.

Standard Approaches Remain the Foundation

Currently, the most evidence-based approaches for cannabis use disorder include:

• Behavioral therapies (CBT, motivational interviewing)
• Support groups
• Contingency management
• Gradual tapering with support
• Treatment for co-occurring mental health conditions

These should remain the primary focus until we have better evidence for medications.

Talk to Your Doctor

If you’re interested in exploring GLP-1 medications, discuss this with your healthcare provider. They can help you understand:

• Whether a GLP-1 medication might be appropriate for other health conditions you have (like diabetes or obesity)
• The potential risks and benefits
• That there’s only preliminary evidence for CUD specifically
• Other options for treating cannabis use disorder
• Resources for behavioral support

Consider the Context

If you have diabetes or obesity and are considering a GLP-1 medication for those conditions, it’s worth knowing that the study found associations with lower CUD rates in those populations. However, this doesn’t mean the medication will definitely help with cannabis use, and it shouldn’t be the primary reason for taking it.

Safety Considerations

The study didn’t report safety data specific to people with cannabis use disorder. GLP-1 medications can have side effects including:

• Nausea and vomiting
• Gastrointestinal issues
• Potential interactions with other substances

If you’re considering these medications, make sure your doctor is aware of your cannabis use and any other substances you’re using.

The Research Landscape

The finding that semaglutide was associated with lower cannabis use disorder rates has generated interest in whether GLP-1 medications might help with substance use more broadly. However, we need careful research to understand:

• Whether these medications actually reduce cannabis use (not just diagnoses)
• How they compare to established CUD treatments
• Whether they’re safe for people with CUD
• Who might benefit most
• What the optimal dosing and duration would be
• Whether effects are sustained after stopping the medication

These are important questions that deserve dedicated research. The preliminary findings are encouraging, but they’re just the beginning of understanding whether GLP-1 medications have a role in treating cannabis use disorder.

Conclusion

GLP-1 medications like semaglutide have shown promising associations with reduced cannabis use disorder diagnoses in observational research. In large studies of patients with obesity and type 2 diabetes, semaglutide was associated with 38-60% lower risks of developing or recurring cannabis use disorder compared to other medications.

However, these findings come with important caveats:

• The study was observational and cannot prove causation
• It didn’t measure actual cannabis use, only diagnoses
• It didn’t compare against standard CUD treatments
• Safety data specific to CUD patients is lacking
• The populations studied were different from people seeking CUD treatment

Randomized controlled trials are needed to establish whether GLP-1 receptor agonists are actually effective and safe for treating cannabis use disorder. Until that research is conducted, we’re working with promising but preliminary evidence.

For people struggling with cannabis use disorder, the most evidence-based approaches remain behavioral therapies and support programs. If you’re considering GLP-1 medications, discuss this with your healthcare provider, understand the limitations of the current evidence, and don’t rely on these medications as a substitute for established treatment approaches.

As research continues, we may learn more about whether GLP-1 medications can help people break free from cannabis use disorder. For now, the findings suggest it’s worth investigating further, but we need proper clinical trials to know for certain whether these medications can help treat this form of THC poisoning.